Islet Cell Transplantation

Orchard T. Diabetes: a time for excitement and concern. BMJ 1998; 317: 691–2

Bell J. , Hockaday T. Diabetes mellitus. In: Ledingham J. , Warreil D. , eds. Concise Oxford Textbook of Medicine. Oxford: Oxford University Press, 2000: 735–70

The Diabetes Control, and Complications Trial Research Group., Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997; 46: 271–86

Bartlett S. , Schweitzer E. , Johnson L. Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation: a prospective trial of tacrolimus immunosuppression with percutaneous biopsy. Ann Surg 1996; 224: 440–52

UKTSSA. Transplant Activity 1999. UKTSSA: 2000

Brendel M. , Hering B. , Schulz A. , Bretzel R. International Islet Transplant Registry Newsletter 2001, 8(1)

Hering B.J. , Ricordi C. Islet transplantation for patients with type 1 diabetes. Graft 1999; 2: 12–27

Shapiro J. , Lakey J.R.T. , Ryan E.A. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230–8

McAlister V.C. , Gao Z. , Peltekian K. Sirolimus–tacrolimus combination immunosuppression. Lancet 2000; 355: 376 and 356: 179–80

Vincenti F. , Kirkman R. , Light S. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161–5

Jordan M.I. , Shapiro R. , Vivas C.A. FK506 ‘rescue’ for resistant rejection of renal allografts under primary cyclosporin at immunosuppression. Transplantation 1994; 57: 860–5

Sehgal S.N. , Bansbach CC. An in vitro immunological profile of rapamycin. Ann NY Acad Sci 1993; 685: 58–67

Groth C.G. , Backman L. , Morales J.M. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 1036–42

Yakimets W.J. , Lakey J.R. , Yatscoff R.W. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporin therapy at low doses: rapamycin eficacy is blood level related. Transplantation 1993; 56: 1293–8

Nomikos I.N. , Prowse S.J. , Caretenuto P. Combined treatment with nicotinamide and desferrioxamine prevents islet allograft destruction in NOD mice. Diabetes 1986; 35: 1302–4

Stevens R.B. , Ansite J.D. , Mills C.D. Nitric oxide mediates early dysfunction of rat and mouse islets after transplantation. Transplantation 1996; 61: 1740–9

Bottino R. , Fernandez L.A. , Ricordi C. Transplantation of allogeneic islets of Langerhans in the rat liver—effect of macrophage depletion on graft survival and microenvironment activation. Diabetes 1998; 47: 316–23

Nomikos I.N. , Wang Y. , Lafferty KJ. Involvement of O₂ radicals in autoimmune diabetes. Immunol Cell Biol 1989; 67: 85–7

Ramiya V.K. , Maraist M. , Arfors K.G. Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells. Nat Med 2000; 6: 278–82

Soria B. , Roche E. , Berna G. Insulin-secreting cells derived from embryonic stem cells normalize glycaemia in streptozocin-induced diabetic mice. Diabetes 2000; 49: 157–61

Bonner-Weir S. , Taneja M. , Weir G. In vitro cultivation of human islets from expanded ductal tissue. Proc Natl Acad Sci USA 2000; 97: 8004

De La Tour D. , Demeterco C. , Yoo S-J Glucose responsive insulin secretion from pancreatic beta cell line. Diabetes 2000: A31